CZ295768B6
(cs)
*
|
1998-12-07 |
2005-10-12 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující
|
DK1137666T5
(da)
|
1998-12-07 |
2009-10-05 |
Univ Tulane |
GLP-1-analoger
|
EP1305338A2
(fr)
*
|
2000-08-02 |
2003-05-02 |
Theratechnologies Inc. |
Peptides biologiques modifies presentant une activite renforcee
|
EP1970072A1
(fr)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Utilisation de peptides GLP-2 pour le traitement d'hyperparathyroïdie
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
CA2430934C
(fr)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
Procede de production de preparations d'une substance bioactive a liberation prolongee a l'aide de gaz haute pression
|
GB0100196D0
(en)
*
|
2001-01-04 |
2001-02-14 |
Anmat Technology Ltd |
Peptides
|
DE60228972D1
(de)
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
RU2353625C2
(ru)
*
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
AU2003271452A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
WO2004037859A1
(fr)
*
|
2002-10-11 |
2004-05-06 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Derives de glp-1 et preparations d'absorption transmucosale de ceux-ci
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
JP2007524579A
(ja)
*
|
2003-02-19 |
2007-08-30 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1の類似体
|
US7847063B2
(en)
*
|
2003-03-28 |
2010-12-07 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
GLP-1 derivative
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
JP4936884B2
(ja)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
EP2292253A3
(fr)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Compositions pharmaceutiques stabilisées de peptides
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
WO2005058955A1
(fr)
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogues du glp-1
|
JP2007514752A
(ja)
*
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
BRPI0417717A
(pt)
|
2003-12-18 |
2007-04-03 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
AU2005203925A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Glucagon-Like Peptide-1 analogs with long duration of action
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
EP1841448A2
(fr)
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Compositions pharmaceutiques et procedes pour le retablissement de masse et de fonction de cellule-beta
|
WO2006083761A2
(fr)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solutions de solvant/polymere utilisees comme vehicules de suspension
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
CA2596926A1
(fr)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Composes glp-1 avances
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
US8236759B2
(en)
|
2005-06-30 |
2012-08-07 |
Ipsen Pharma Sas |
GLP-1 pharmaceutical compositions
|
ES2572952T3
(es)
|
2005-11-07 |
2016-06-03 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
MX2008013304A
(es)
|
2006-04-20 |
2008-10-27 |
Amgen Inc |
Compuestos de peptido 1 tipo glucagon.
|
CN101453982B
(zh)
|
2006-05-30 |
2011-05-04 |
精达制药公司 |
两件式内部通道渗透递送系统流动调节器
|
JP4537495B2
(ja)
*
|
2006-06-23 |
2010-09-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
インスリン分泌性ペプチドの合成
|
GB0612669D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Leeds |
Biomarkers for preeclampsia
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
WO2008021133A2
(fr)
|
2006-08-09 |
2008-02-21 |
Intarcia Therapeutics, Inc. |
systèmes d'administration osmotiques et ensembles pistons
|
US20100179131A1
(en)
|
2006-09-07 |
2010-07-15 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
US20100137204A1
(en)
*
|
2006-12-29 |
2010-06-03 |
Zheng Xin Dong |
Glp-1 pharmaceutical compositions
|
JP2010523473A
(ja)
*
|
2006-12-29 |
2010-07-15 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
Glp−1医薬組成物
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CA2677932A1
(fr)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Co-agonistes des recepteurs du glucagon/glp-1
|
EP2157967B1
(fr)
|
2007-04-23 |
2013-01-16 |
Intarcia Therapeutics, Inc |
Formulations en suspension de peptides insulinotropes et leurs utilisations
|
EP2025674A1
(fr)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
JP5606314B2
(ja)
|
2007-09-05 |
2014-10-15 |
ノボ・ノルデイスク・エー/エス |
A−b−c−d−で誘導体化されたペプチドとその治療用途
|
WO2009035540A2
(fr)
*
|
2007-09-07 |
2009-03-19 |
Ipsen Pharma S.A.S. |
Analogues d'exendine-4 et exendine-3
|
CN101835794A
(zh)
|
2007-10-27 |
2010-09-15 |
霍夫曼-拉罗奇有限公司 |
使用固相和溶液相组合技术的促胰岛素肽合成法
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
AU2008334783A1
(en)
*
|
2007-12-11 |
2009-06-18 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
EP2240155B1
(fr)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
|
CN102105159B
(zh)
*
|
2008-06-17 |
2015-07-08 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
PE20100255A1
(es)
|
2008-06-17 |
2010-04-25 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
EP4074327A1
(fr)
|
2008-06-27 |
2022-10-19 |
Duke University |
Agents thérapeutiques comprenant des peptides de type élastine
|
WO2010015668A1
(fr)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk A/S |
Protéines conjuguées à efficacité in vivo prolongée
|
EP2328922A4
(fr)
*
|
2008-08-07 |
2013-01-02 |
Ipsen Pharma Sas |
Analogues de polypeptide insulinotrope glucose-dépendant
|
KR20130133104A
(ko)
*
|
2008-08-07 |
2013-12-05 |
입센 파마 에스.에이.에스 |
포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
|
CN102171243A
(zh)
*
|
2008-08-07 |
2011-08-31 |
益普生制药股份有限公司 |
N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
|
AU2009280012B2
(en)
*
|
2008-08-07 |
2012-12-06 |
Ipsen Pharma S.A.S. |
Truncated analogues of glucose-dependent insulinotropic polypeptide
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
DK2370461T3
(da)
|
2008-12-15 |
2013-12-16 |
Zealand Pharma As |
Glucagonanaloger
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
DK2370462T3
(da)
|
2008-12-15 |
2014-09-08 |
Zealand Pharma As |
Glucagon-analoger
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
BRPI0922969A2
(pt)
|
2008-12-19 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
pró-farmaco de amida baseado na superfamília de glucagon peptídeo.
|
JP2012513626A
(ja)
|
2008-12-23 |
2012-06-14 |
エフ.ホフマン−ラ ロシュ アーゲー |
収集装置で作動する構造化収集手続の実装、実行、データ収集、及びデータ分析のための管理方法及びシステム
|
US20100183876A1
(en)
*
|
2008-12-23 |
2010-07-22 |
Hell Andre |
Process for the Preparation of a Peptide Powder Form
|
AU2010207725B2
(en)
|
2009-01-22 |
2015-06-11 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
EP2216042A1
(fr)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
Compositions pharmaceutiques analogues au GLP-1
|
JP2012525348A
(ja)
*
|
2009-05-01 |
2012-10-22 |
エフ.ホフマン−ラ ロシュ アーゲー |
固相及び溶液相の組み合わせ技術を用いたインスリン分泌促進ペプチド合成
|
IN2012DN00377A
(fr)
|
2009-06-16 |
2015-08-21 |
Univ Indiana Res & Tech Corp |
|
US9156901B2
(en)
|
2009-07-13 |
2015-10-13 |
Ditte Riber |
Acylated glucagon analogues
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
EP2470552B1
(fr)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
|
CN104323981B
(zh)
|
2009-09-28 |
2019-03-12 |
精达制药公司 |
基本稳态药物递送的快速建立和/或终止
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
AU2011208625C1
(en)
|
2010-01-22 |
2022-08-18 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
CA2787895A1
(fr)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Composes stables d'hormone de croissance
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
WO2011136361A1
(fr)
|
2010-04-30 |
2011-11-03 |
株式会社 三和化学研究所 |
Peptide permettant d'améliorer la stabilité in vivo d'une substance physiologiquement active ou analogues et substance physiologiquement active et analogues présentant une amélioration de la stabilité in vivo
|
EP2582709B1
(fr)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
|
US20110313131A1
(en)
|
2010-06-21 |
2011-12-22 |
Christelle Carl |
Reversed phase hplc purification of a glp-1 analogue
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
PE20130338A1
(es)
*
|
2010-06-24 |
2013-03-16 |
Zealand Pharma As |
Analogos del glucagon
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
RS56998B1
(sr)
|
2010-12-16 |
2018-05-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
|
WO2012088116A2
(fr)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Analogues du glucagon présentant une activité de récepteur de gip
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EP2683702B1
(fr)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
|
EP2683701B1
(fr)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
|
WO2012120055A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120052A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
|
EP2683698B1
(fr)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120057A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
MX355361B
(es)
|
2011-04-12 |
2018-04-17 |
Novo Nordisk As |
Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
DK2723367T3
(en)
|
2011-06-22 |
2017-07-17 |
Univ Indiana Res & Tech Corp |
Glucagon / GLP-1 receptor-CO-AGONISTS
|
EP2734239A2
(fr)
|
2011-07-18 |
2014-05-28 |
Arts Biologics A/S |
Composé hormone lutéinisante (lh) biologiquement actif à longue action
|
EP2567959B1
(fr)
|
2011-09-12 |
2014-04-16 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
WO2013037390A1
(fr)
|
2011-09-12 |
2013-03-21 |
Sanofi |
Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
WO2013045413A1
(fr)
|
2011-09-27 |
2013-04-04 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
RU2641198C3
(ru)
|
2012-03-22 |
2021-12-10 |
Ново Нордиск А/С |
Композиции glp-1 пептидов и их получение
|
SG11201407137PA
(en)
|
2012-05-03 |
2014-11-27 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
WO2013170636A1
(fr)
|
2012-05-18 |
2013-11-21 |
爱德迪安(北京)生物技术有限公司 |
Protéine et conjugué protéique pour le traitement du diabète et applications associées
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
EP2873422A4
(fr)
|
2012-07-10 |
2015-12-30 |
Takeda Pharmaceutical |
Préparation pharmaceutique pour l'injection
|
KR101848303B1
(ko)
|
2012-07-10 |
2018-04-13 |
삼성전자주식회사 |
전력 전송을 제어하기 위한 방법 및 이를 위한 전력 송신기
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
CN105142621A
(zh)
|
2012-10-24 |
2015-12-09 |
国家健康科学研究所 |
用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
|
CN104936610A
(zh)
|
2012-11-13 |
2015-09-23 |
益普生制药股份有限公司 |
Glp-1类似物的纯化方法
|
WO2014077801A1
(fr)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Procédé de purification pour préparer du tasoglutide de haute pureté
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
WO2014209886A1
(fr)
|
2013-06-23 |
2014-12-31 |
Wisconsin Alumni Research Foundation |
Analogues polypeptidiques alpha/bêta du peptide-1 apparenté au glucagon
|
CN103536907B
(zh)
*
|
2013-07-18 |
2015-10-21 |
上海交通大学医学院附属瑞金医院 |
利拉鲁肽在骨质疏松治疗药物中的应用
|
MX368436B
(es)
|
2013-10-17 |
2019-10-03 |
Zealand Pharma As |
Analogos de glucagon acilados.
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
EP3065767B1
(fr)
|
2013-11-06 |
2020-12-30 |
Zealand Pharma A/S |
Composés agonistes doubles gip-glp-1 et procédés
|
WO2015067716A1
(fr)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Composés agonistes triples glucagon-glp-1-gip
|
WO2015081891A1
(fr)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Pro-fragments bioréversibles pour médicaments contenant de l'azote et de l'hydroxyle
|
WO2015086686A2
(fr)
*
|
2013-12-13 |
2015-06-18 |
Medimmune Limited |
Peptides résistant aux protéases
|
ES2741507T3
(es)
|
2014-04-07 |
2020-02-11 |
Novo Nordisk As |
Compuestos de glp-1 acilados doblemente
|
PL3189072T3
(pl)
|
2014-09-05 |
2019-04-30 |
Univ Copenhagen |
Analogi peptydowe gip
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
AU2015340586B2
(en)
|
2014-10-29 |
2020-04-30 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
BR112017022009A2
(pt)
|
2015-04-16 |
2018-07-03 |
Zealand Pharma A/S |
?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico?
|
WO2016196851A2
(fr)
|
2015-06-03 |
2016-12-08 |
Intarcia Therapeutics, Inc. |
Systèmes de mise en place et de retrait d'implant
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
MX2018014016A
(es)
|
2016-05-16 |
2019-08-01 |
Intarcia Therapeutics Inc |
Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
ES2972848T3
(es)
|
2017-05-31 |
2024-06-17 |
The Univ Of Copenhagen |
Análogos de péptido GIP de acción prolongada
|
IL275778B2
(en)
|
2018-02-02 |
2023-12-01 |
Novo Nordisk As |
Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
|
IL311177A
(en)
*
|
2018-03-23 |
2024-04-01 |
Carmot Therapeutics Inc |
Modulators of protein-coupled receptors - G
|
SI4122954T1
(sl)
|
2018-04-05 |
2024-07-31 |
Sun Pharmaceutical Industries Limited |
Novi analogi GLP-1
|
WO2019200594A1
(fr)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
Dérivé de glp-1 acylé
|
CA3116023A1
(fr)
|
2018-10-11 |
2020-04-16 |
Intarcia Therapeutics, Inc. |
Polypeptides analogues d'amyline humaine et procedes d'utilisation
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
MX2021006505A
(es)
|
2018-12-03 |
2021-10-01 |
Antag Therapeutics Aps |
Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
|
WO2022157747A2
(fr)
|
2021-01-25 |
2022-07-28 |
Mylan Ireland Limited |
Compositions peptidiques pharmaceutiques et leurs procédés de préparation
|
CN114874314B
(zh)
*
|
2021-12-28 |
2022-11-11 |
北京惠之衡生物科技有限公司 |
一种高表达glp-1类似物的重组工程菌及其构建方法
|
TW202421654A
(zh)
|
2022-09-28 |
2024-06-01 |
丹麥商西蘭製藥公司 |
治療肥胖之方法
|